Efficacy in the margins of NHL with ibrutinib
- PMID: 28428233
- DOI: 10.1182/blood-2017-02-769042
Efficacy in the margins of NHL with ibrutinib
Conflict of interest statement
Conflict-of-interest disclosure: P.M.B. has consulted for and received research funding from Pharmacyclics and AbbVie.
Comment on
-
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. Blood. 2017. PMID: 28167659 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources

